skip to Main Content

Ninalia – NIPT


Screening for aneuploidies such as Downs SyndromeEdwardsPatauTurnerJacobs and Klinefelter Syndromes, plus Trisomy X.

  • 10ml blood sample required from the expectant Mother
  • FREE gender identification (optional)
  • Available from 10 weeks of pregnancy
  • Results available within 5 working days of sample arriving in laboratory

If using a mobile device – please continue scrolling to see full product information

Out of stock


The Ninalia test screens the aneuploidies of chromosomes 21, 18, 13, sex chromosomes (X and Y) – Downs, Edwards, Patau, Turner, Jacobs and Klinefelter Syndromes, plus Trisomy X – Ninalia also includes Gender Identification* (optional).

*We are unable to provide gender identification in dichorionic twins – Dichorionic means there are two placentas.

Suitable for single and twin pregnancies, achieved by natural conception or IVF treatment.

Thanks to the recent introduction in the clinical practice of the Ninalia® screening test of the new high-resolution FAST  technology (reading depth ~ 30 million sequences), the results of the test is available from 5 working days, maintaining the same levels of sensitivity and specificity of the test.


During the pregnancy, some fragments of the fetal DNA circulate in the maternal blood and are detectable starting from the 5th week of gestation. The circulating fetal DNA quantity increases with the increasing gestational period, and from the 10th week of gestation it is sufficient for the Ninalia test to guarantee a high specificity and sensitivity of the test.

The test requires a 10ml blood sample* – this will need to be collected by your midwife, GP or Private Hospital – there may be a small charge for this service.

*If you live local to one of our boutiques, you can buy your test online and opt for a complimentary blood draw from our Manchester and Lancashire based boutiques. PLUS a FREE reassurance scan worth £45! 


Traditional screening offered during pregnancy is currently called the combined test. This is an ultrasound scan to measure the nuchal translucency (NT) and a blood test. This is much less accurate than NIPT and it only detects around 85% of babies with Down’s syndrome.

The Ninalia test has a higher detection rate than the current combined test offered to pregnant women. This means that fewer pregnant women will undergo unnecessary invasive follow-up procedures such as amniocentesis or CVS which are stressful, painful and can carry a small risk of miscarriage.


The Positive Predictive Value (PPV) is the probability that a high-risk result indicates the presence of Down’s syndrome. The PPV takes into account how common Down’s syndrome is in the population. For the following Trisomys, these are the test’s performance characteristics; Trisomy 21 – 99.21%, Trisomy 18 – 97.14%, Trisomy 13 – 93.52% and Monosomy X – 71.67%.

The Detection Rate (sensitivity) of Ninalia is over 99%, which means that nearly every case of Down’s syndrome will be detected with very few false negative results (affected pregnancies falsely screened as low risk).

False Positive Rate (FPR) is the proportion of pregnancies that do not have the syndrome but have screened as high risk. A false positive result means that although NIPT indicates a high risk of trisomy 21, the fetus does not have this condition. For the following Trisomys, these are the test’s performance characteristics; Trisomy 21 – 0.01%, Trisomy 18 – 0.01%, Trisomy 13 – 0.01% and Monosomy X – 0.04%.

We always recommend that results are discussed with your Healthcare Professional

Please take the time to familiarise yourself with our NIPT FAQs before placing your order

Please click here to see Brochure